NHS
Cambridge
University Hospitals
NHS Foundation Trust

Date

Dear Dr *Name,*

Re: Participant name:
Date of Birth:
Hospital Number:
Address:

RE: Multi-Arm Therapeutic Study in Pre-ICU patients admitted with Covid-19 Repurposed Drugs (TACTIC-R)

Selected Arm: Standard of care

I am writing to inform you that your patient has agreed to participate in the above clinical trial at local hospital name.

TACTIC-R is a multicentre, parallel arm, open-label randomised controlled trial sponsored by Cambridge University Hospitals NHS Foundation Trust. The aim of the study is to identify if immunomodulatory drugs can lower the overactive immune response that has been observed to drive the severe lung and other organ damage in COVID-19 patients at late stage 1/early stage 2 disease. Additionally, risk markers will be used to monitor disease progression in response of the therapeutic agents, thereby aiming to reduce the disease progression.

More specifically, this study is evaluating the efficacy of the interventions of baricitinib, or ravulizumab, compared to standard of care treatment. **Your patient has been selected for the standard of care arm.**

For further information on the study, I have enclosed a copy of the Participant Information Sheet for your reference, however, if you have any queries or require further information please contact the study team (Insert local contact details including contact number and website if available).

In the event of an emergency please call:

Insert emergency telephone number which must match the telephone number on the PIS

Should you have any concerns about your patient participating in the study, please feel free to contact a member of the study team

Yours Sincerely,

PI name

Study Team Contact Information:

Local Contact Name

Hospital

Role

Telephone number

Encs: Participant Information Sheet, version *(insert version number)* dated *(insert date)*